APOA2 and carcinoma of duodenum: The decrease in apoAII-ATQ/AT relative to healthy controls was particularly dramatic in patients with IDACP, pancreatic diseases other than IDACP, cholangiocarcinoma, and duodenal carcinoma (Fig. 4A and Supplemental Table 3).